Finger mass biopsy - Medium 1-3 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Biopsy of finger lesion.

₹370₹529

30% OFF

Finger Mass Biopsy - Medium 1-3 cm

Why is it done?
- To obtain tissue samples from an abnormal mass or lesion on the finger for histopathological examination and definitive diagnosis
- To differentiate between benign and malignant lesions, including ganglions, lipomas, fibromas, cysts, and skin cancers
- When imaging studies (ultrasound, MRI) show suspicious findings requiring tissue confirmation
- When a palpable mass persists despite clinical observation or when rapid growth is noted
- To guide treatment decisions and determine prognosis based on tissue diagnosis
- To evaluate lesions associated with symptoms such as pain, functional impairment, or cosmetic concerns
Normal Range
- Normal/Benign Result: Histopathological findings consistent with benign tissue (ganglion cyst, lipoma, fibroma, epidermal cyst, or other non-malignant lesion)
- Negative Finding: No malignant cells present; no evidence of carcinoma, melanoma, or sarcoma
- Positive/Abnormal Result: Malignant cells identified (squamous cell carcinoma, basal cell carcinoma, melanoma, sarcoma, or other malignancy)
- Borderline/Atypical Finding: Dysplastic or atypical cells present; may require repeat sampling or further investigation
- Measurement Unit: Histological tissue classification and cellular morphology analysis with size 1-3 cm (medium lesions)
Interpretation
- Benign Lesions: Ganglion cysts, lipomas, and fibromas are non-cancerous and generally do not require aggressive treatment unless causing functional impairment or pain. These findings are reassuring and may be managed conservatively.
- Malignant Findings: Confirmation of cancer requires immediate specialist consultation, staging studies (CT/MRI), and development of treatment plan including possible wide surgical excision, chemotherapy, or radiation depending on tumor type and grade.
- Atypical/Dysplastic Changes: Suggests premalignant potential or inadequate sampling. Typically requires repeat biopsy, close monitoring, or consideration of excisional biopsy with wider margins.
- Inflammatory Conditions: May indicate infection, inflammatory arthritis, or granulomatous disease requiring appropriate antimicrobial or immunosuppressive therapy.
- Factors Affecting Results: Specimen size and quality, adequacy of sampling, tissue fixation, staining techniques, immunohistochemical studies, patient age, lesion location, clinical presentation, immunosuppression status, and prior treatments.
- Clinical Significance: Tissue diagnosis is the gold standard for distinguishing benign from malignant lesions. Results directly impact treatment decisions and prognosis. Early detection of malignancy in medium-sized lesions (1-3 cm) often portends better outcomes compared to larger, delayed diagnoses.
Associated Organs
- Primary Organ Systems: Integumentary system (skin), musculoskeletal system (tendons, joints, bone), lymphatic system (regional lymph nodes)
- Benign Conditions: Ganglion cysts (from joint synovial tissue), lipomas (fatty tissue), fibromas (fibrous tissue), epidermoid cysts, sebaceous cysts, keratosis
- Malignant Conditions: Squamous cell carcinoma, basal cell carcinoma, melanoma, synovial sarcoma, liposarcoma, fibrosarcoma, leiomyosarcoma
- Associated Systemic Diseases: Rheumatoid arthritis, tuberculosis, sarcoidosis, fungal infections, lymphoma with cutaneous involvement
- Potential Complications of Malignancy: Local invasion, regional lymph node metastasis, distant metastasis, bone involvement, vascular invasion, neural compression
- Biopsy-Related Risks: Infection, bleeding, nerve injury, tendon damage, seeding of malignant cells (rare with proper technique), wound complications, pain
Follow-up Tests
- If Benign Diagnosis: Clinical follow-up as needed; ultrasound or MRI only if symptoms develop or lesion changes; no routine surveillance required
- If Malignant Diagnosis: CT scan or MRI for staging; chest X-ray or CT chest for metastasis screening; regional lymph node ultrasound or biopsy; PET-CT for high-grade sarcomas; molecular/genetic testing if indicated
- If Atypical/Dysplastic: Repeat biopsy with wider margins; excisional biopsy; close clinical and radiological follow-up every 3-6 months
- Immunohistochemistry/Special Stains: S-100, HMB-45, Melan-A for melanoma; CD34, TLE1 for synovial sarcoma; CD117, DOG1 for GIST; ER/PR, HER2 for breast tissue metastasis
- Molecular Testing: BRAF mutation (melanoma), NRAS mutation, KIT mutation, PDGFRA mutation, EWSR1 translocation for sarcoma subtyping
- Infectious Workup (if indicated): Fungal culture and PCR, AFB stain and culture for tuberculosis, bacterial culture
- Surgical Consultation: Oncology consultation for malignant lesions; hand specialist for functional assessment
Fasting Required?
- Fasting Required: No
- Patient Preparation: Standard skin antisepsis with chlorhexidine or povidone-iodine; sterile draping of operative field; local anesthesia (lidocaine 1% or similar) with or without epinephrine
- Medications to Avoid: Discontinue anticoagulants (warfarin, dabigatran) 3-5 days prior if possible; hold antiplatelet agents (aspirin, clopidogrel) 5-7 days before procedure; NSAIDs may increase bleeding risk. Consult with cardiologist regarding anticoagulation timing if cardiac condition exists.
- Special Instructions: Inform provider of allergies (especially lidocaine or iodine); report bleeding disorders or anticoagulation therapy; remove jewelry from biopsied hand; wear loose clothing; bring list of current medications; arrive 15 minutes early
- Post-Procedure Care: Keep wound clean and dry; change dressing as directed; elevate hand to reduce swelling; avoid immersion in water for 7-10 days; watch for signs of infection (increasing redness, warmth, drainage); results typically available in 5-10 business days

How our test process works!